The 2016 European Thyroid Association/European Group on Graves' Orbitopathy Guidelines for the Management of Graves' Orbitopathy - Wikidata - awgldk - TriplyDB

The 2016 European Thyroid Association/European Group on Graves' Orbitopathy Guidelines for the Management of Graves' Orbitopathy

The 2016 European Thyroid Association/European Group on Graves' Orbitopathy Guidelines for the Management of Graves' Orbitopathy

http://www.wikidata.org/entity/Q36811289

about

Establishment of a tear protein biomarker panel differentiating between Graves' disease with or without orbitopathy.Update on thyroid-associated Ophthalmopathy with a special emphasis on the ocular surface Influence of short-term selenium supplementation on the natural course of Hashimoto's thyroiditis: clinical results of a blinded placebo-controlled randomized prospective trial.A 2016 Italian Survey about the Clinical Use of Selenium in Thyroid Disease.Clinical and imaging evaluation of the response to intravenous steroids in patients with Graves' orbitopathy and analysis on who requires additional therapy.Time course of Graves' orbitopathy after total thyroidectomy and radioiodine therapy for thyroid cancer.Rituximab therapy in pemphigus and other autoantibody-mediated diseases.Selenium and Thyroid Disease: From Pathophysiology to Treatment.Management of hyperthyroidism due to Graves' disease: frequently asked questions and answers (if any).Natural course of mild Graves' orbitopathy: is it a chronic remitting or a transient disease?Thyroid eye disease: a review.Does early response to intravenous glucocorticoids predict the final outcome in patients with moderate-to-severe and active Graves' orbitopathy?The effect of orbital radiation therapy on thyroid-associated orbitopathy complicated with dysthyroid optic neuropathy.Graves' orbitopathy, idiopathic orbital inflammatory pseudotumor and Epstein-Barr virus infection: a serological and molecular study.Thickness of Extraocular Muscle and Orbital Fat in MRI Predicts Response to Glucocorticoid Therapy in Graves' Ophthalmopathy.Selenium in the Treatment of Thyroid Diseases.Treatment of Graves' ophthalmopathy with an in-house Phosphorus-32 source: Initial clinical observations Selenium in the Treatment of Thyroid Diseases: An Element in Search of the Relevant Indications?Does Graves' Orbitopathy Ever Disappear? Answers to an Old Question.[Management of moderate and severe dysthyroid orbitopathy: about 22 cases].Thyroid-associated orbitopathy in patients with thyroid carcinoma: A case report of 5 cases.Quantitative Analysis of Inflammation in Orbital Fat of Thyroid-associated Ophthalmopathy Using MRI Signal Intensity.A genome-wide DNA methylation analysis in peripheral blood from patients identifies risk loci associated with Graves' orbitopathy.Thyroid disorders in alemtuzumab-treated multiple sclerosis patients: a Belgian consensus on diagnosis and management.Measuring TSH receptor antibody to influence treatment choices in Graves' disease.Changing trend in referral to secondary care specialist thyroid eye disease clinic following the Amsterdam declaration.Natural history of graves' orbitopathy after treatment.Balanced (endoscopic medial and transcutaneous lateral) orbital decompression in Graves' orbitopathy.A single-center retrospective study of factors related to the effects of intravenous glucocorticoid therapy in moderate-to-severe and active thyroid-associated ophthalmopathy.Orbital radiotherapy plus three-wall orbital decompression in a patient with rare ocular manifestations of thyroid eye disease: case report.Use of low-dose radioiodine ablation for Graves' orbitopathy: results of a pilot, perspective study in a small series of patients.Occurrence of Graves' Orbitopathy and Graves' Hyperthyroidism after a Trauma to the Eye.Action of three bioavailable antioxidants in orbital fibroblasts from patients with Graves' orbitopathy (GO): a new frontier for GO treatment?Teprotumumab: a new avenue for the management of moderate-to-severe and active Graves' orbitopathy?Safety of total thyroid ablation in patients with Graves' orbitopathy.Cutting-edge endonasal surgical approaches to thyroid ophthalmopathy.2018 European Thyroid Association Guideline for the Management of Graves' Hyperthyroidism Orbital decompression in the system of treatment for complicated thyroid eye disease: case report and literature review Influence of Methylprednisolone Pulse Therapy on Liver Function in Patients with Graves' Orbitopathy Blood Pressure Profile and N-Terminal-proBNP Dynamics in Response to Intravenous Methylprednisolone Pulse Therapy of Severe Graves' Orbitopathy

P2860

Q33574320-4BF15B0D-BB04-4712-A036-1B6C6CFE5261 Q33802192-666CFD34-63E1-483A-8B92-732E4E53B5B3 Q36116207-9F2F0707-52CA-4F45-8A3D-1CA6510BB79A Q37387874-6A5ECBEF-42C5-4EB1-B134-EF643C49C3A9 Q37426835-175F1170-6717-42EF-8522-A9EA4DB7DF7D Q37467757-07AE405B-5E52-42D8-A2FD-381F17327FB7 Q37620483-2E432530-E4D1-4F59-8E84-1CF342B130FA Q37640141-E80A5E36-0794-441E-B77E-8590723C3C4B Q38869637-3ECE922F-6441-4549-A0AD-C9AF6C7C85D1 Q38963406-8DAEC50D-B30F-4874-8B10-C2FBB5084250 Q38971992-735858AB-D266-444A-B167-C17DB0C0CFE9 Q38972962-19AF75E2-E3F7-45DB-AFF4-021B383A9FF6 Q39303459-6123F085-5A2D-4B4A-A9E3-878DF6CCDFA4 Q40405974-A345768F-3EBD-4446-8E7F-7D9A808224A8 Q41463534-96B93AB1-56BD-4B16-A17F-D4F0D75B504D Q41641247-14FDF32E-4E74-467B-820D-375E8ACC587B Q41665052-564810D7-8946-44C4-A528-FA89380FCE4C Q42375814-3A5546D5-BBA3-4817-AC78-66060406EF61 Q42667849-09A23031-5679-4B55-935D-024198279530 Q46190198-B2313EDF-6961-44F8-BECD-42C2CCC44D3B Q47096983-C744C5AA-3357-41AF-9DE9-A99A43981938 Q47114849-921D986B-FCD0-497A-BE78-5F967787B8F2 Q47299466-8D48A570-5AF8-48B3-9125-823ED28DFD91 Q47556203-509051BD-5148-4007-ADCE-69B65F936C35 Q48125225-06187DC1-E334-48C5-84BE-00243C268CC9 Q48259178-31961BDF-751C-462B-BCE2-67E7DD7EB785 Q48318128-5C55E24F-CE32-4B6B-937A-AE060FB49215 Q48584603-18E0BEBA-B6CE-4834-BD51-1D8E3B40F0B9 Q49796061-0AB93943-00B4-4139-8E92-9B9F38BAE2EA Q50156883-E628FD82-FEC3-4148-B44A-3A2AC562647C Q50254727-547A5040-D0AD-4697-B02C-1B234A992FA2 Q52624186-ED9E9AD5-710E-475B-876B-E19857F3C910 Q53192241-CCB8CC35-5347-450E-9DE4-84ECBA7F1671 Q53207209-A2B421FF-87DA-45FD-BC3F-1DFC565ECE2B Q54432685-73E7B0F0-8C0D-4C6F-B1E7-BB3B4E579CB1 Q55001461-C57FEE25-CBDF-4222-8115-92F233240327 Q57136607-D91A6118-78B6-4A4D-A3E0-67AEED8E49DC Q57487226-BB378A74-371E-4D65-9BB2-052C2DEF7685 Q58695115-ED67A0AF-46B7-44AD-86B3-2328F176817F Q59134155-376851A5-B485-4128-BC63-4E43867337F9

P2860

The 2016 European Thyroid Association/European Group on Graves' Orbitopathy Guidelines for the Management of Graves' Orbitopathy

http://www.wikidata.org/entity/Q36811289

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

The 2016 European Thyroid Asso ...... agement of Graves' Orbitopathy

@ast

The 2016 European Thyroid Asso ...... agement of Graves' Orbitopathy

@en

type

label

The 2016 European Thyroid Asso ...... agement of Graves' Orbitopathy

@ast

The 2016 European Thyroid Asso ...... agement of Graves' Orbitopathy

@en

prefLabel

The 2016 European Thyroid Asso ...... agement of Graves' Orbitopathy

@ast

The 2016 European Thyroid Asso ...... agement of Graves' Orbitopathy

@en

P1433

Q36811289-713095D9-4231-4F2C-9E7B-AB48DCF7D06F

P1476

Q36811289-03A76D81-B4A3-4D63-9328-208223342387

P2093

Q36811289-1B846943-C3CC-4C03-A261-E02A805190D0

Q36811289-2F44BF93-243E-4324-98E9-F024ABF2EB09

Q36811289-3B856536-12BA-4EE4-B633-CF96F1C0CE51

Q36811289-A67904F6-7A6A-4518-80CB-92E2AE07FEAE

Q36811289-A9AB3113-A28A-4C22-A318-E9A240794CB7

Q36811289-C2759180-BE4F-4E9F-B82B-3D9279B9ABA4

Q36811289-DA12B337-D324-48B2-B8C6-85C44AF48DA5

Q36811289-E670BB32-9491-4419-9D67-5BE5363C63D3

P2860

Q36811289-03DB0F73-B3A0-4DED-B6F3-6AFFD7C7B464

Q36811289-04078397-78A0-4CCF-A8ED-97EFFA852587

Q36811289-04B304DB-33CA-4F3C-B01E-A27FAA1400C6

Q36811289-04D75ED0-F4C8-47E0-81A6-F2ABF59681D7

Q36811289-05E7FF9B-9153-4850-BB96-454F6EEAC028

Q36811289-064C286D-3DA3-4485-B344-74ACBE9D05DA

Q36811289-070DA6B2-E6F5-48E9-B743-F4F27DA748B6

Q36811289-0790DA42-0138-4E5A-AEA5-28A52769D63C

Q36811289-0C01AABD-6E2F-4368-81F6-B7700D50ED69

Q36811289-107EA2D3-D4EF-4D56-8FEC-2541941426B1

P304

Q36811289-45477A9B-C625-4D27-B4FC-08B645A9E246

P31

Q36811289-B8082C14-7EC1-4954-8BD2-63E258262A36

P356

Q36811289-B972ED7F-CBEF-435B-9333-8F3E66383EBA

P433

Q36811289-20BF4E5E-5670-46BE-AA0E-2B7F9E64D167

P478

Q36811289-266CC66B-4FD4-4AD9-BE04-1484A9B1741E

P50

Q36811289-1FDA3225-9CA1-4750-91EB-678818393D85

Q36811289-E04ADCB7-0EE2-473D-A4BC-0EF945F75FB4

P577

Q36811289-514FEAE5-FF88-469F-A24B-1289480E279F

P698

Q36811289-5784F91D-F4E9-463F-BF03-E8A9215C0B38

P932

Q36811289-E0C2F7B0-72E6-4214-A389-CEC033ED5C2F

P356

P1433

European thyroid journal : official journal of the European Thyroid Association

P1476

The 2016 European Thyroid Asso ...... agement of Graves' Orbitopathy

@en

P2093

Anja Eckstein

http://www.w3.org/2001/XMLSchema#string

Claudio Marcocci

http://www.w3.org/2001/XMLSchema#string

European Group on Graves' Orbitopathy (EUGOGO)

http://www.w3.org/2001/XMLSchema#string

George J Kahaly

http://www.w3.org/2001/XMLSchema#string

Kostas Boboridis

http://www.w3.org/2001/XMLSchema#string

Lelio Baldeschi

http://www.w3.org/2001/XMLSchema#string

Luigi Bartalena

http://www.w3.org/2001/XMLSchema#string

Wilmar M Wiersinga

http://www.w3.org/2001/XMLSchema#string

P2860

Immunotoxicity of monoclonal antibodies

Critical Appraisal on Orbital Decompression for Thyroid Eye Disease: A Systematic Review and Literature Search

The importance of selenium to human health

Selenium and the course of mild Graves' orbitopathy

Graves' ophthalmopathy

Prospectively recorded and MedDRA-coded safety data of intravenous methylprednisolone therapy in Graves' orbitopathy.

Rituximab treatment of patients with severe, corticosteroid-resistant thyroid-associated ophthalmopathy

Consensus statement of the European Group on Graves' orbitopathy (EUGOGO) on management of GO.

Quality of life in patients with Graves' ophthalmopathy is markedly decreased: measurement by the medical outcomes study instrument.

Long-term results of irradiation for patients with progressive Graves' ophthalmopathy.

P304

9-26

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1159/000443828

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P50

P577

2016-03-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27099835

http://www.w3.org/2001/XMLSchema#string

P932

4836120

http://www.w3.org/2001/XMLSchema#string